Pancreatic Cancer Survival Rate Improves With New Integrated Treatments in Taiwan

Pancreatic cancer, notoriously dubbed the "king of cancers," presents a grim prognosis with a mere 9.8% five-year survival rate, meaning fewer than one in ten patients live beyond this mark. However, a significant shift is underway at Taipei Veterans General Hospital (TVGH), where a multi-modal treatment approach is bringing new hope.

TVGH is pioneering an integrated strategy that combines chemotherapy, particle therapy, advanced surgery, and precision medicine. This comprehensive approach has made it possible for some patients with tumors previously deemed inoperable to undergo "conversion surgery." The hospital reports a 100% satisfaction rate among patients receiving this multi-modal therapy, and it leads globally in the number of successful conversion surgeries performed.

“

Pancreatic cancer remains one of the most challenging and difficult-to-treat cancers, but in recent years, with significant advances in systemic treatment, surgery, particle therapy, and Boron Neutron Capture Therapy (BNCT), it is bringing new dawn to patients.

Chen Wei-ming, president of TVGH, highlighted the ongoing progress in systemic treatments, surgery, particle therapy, and Boron Neutron Capture Therapy (BNCT), which are expanding treatment options. The hospital's heavy particle therapy center, operational for three years, has treated over 800 patients, with about 30% suffering from pancreatic cancer. Early results are encouraging, though more long-term data is needed.

“

Pancreatic cancer treatment is no longer reliant on a single therapy but has become a 'team battle' integrating chemotherapy, radiotherapy, surgery, and precision medicine.

An international conference on multi-modal pancreatic cancer treatment, held at TVGH, emphasized the move from single-modality treatments to a "team battle" approach. This involves integrating chemotherapy, radiotherapy, surgery, and precision medicine. Advances in minimally invasive and robotic surgery mean over 70% of pancreatic surgeries can now be performed robotically.

The conference also explored cutting-edge developments like AI-assisted diagnosis, cancer vaccines, KRAS targeted drugs, and cell immunotherapy. Research on novel pan-RAS inhibitors has shown potential to double the overall survival for patients with metastatic pancreatic cancer, sparking discussions on integrating these into current treatment frameworks. This multi-disciplinary, multi-specialty integration and technological breakthroughs offer a renewed chance for patients with previously untreatable conditions.

“

Through multi-modal, multi-specialty integration and technological breakthroughs, it is possible to give some patients who were previously unable to undergo surgery a new opportunity, adding new treatment options for difficult-to-treat pancreatic cancer.